STATE OF THE ART OF THE TREATMENT OF HIV INFECTIONS (AIDS)

Séminaire de Pathologie Infectieuse / Chaire Francqui (UCL) - 24-04-03

Click here to start

Table of Contents

STATE OF THE ART OF THE TREATMENT OF HIV INFECTIONS (AIDS)

Leading causes of death in Africa, 2000

HIV REPLICATIVE CYCLE

T-20 (enfuvirtide) versus Optimized Regimen Only (TORO 1) Study 1 Efficacy at week 24 in the Intention-to-Treat population

T-20 (enfuvirtide) versus Optimized Regimen Only (TORO 1) Study 1 Time to protocol-defined virologic failures, as of week 24

HIV Reverse Transcriptase

HIV Reverse Transcriptase

HIV REPLICATIVE CYCLE

HIV REPLICATIVE CYCLE

HIV REPLICATIVE CYCLE

Atazanavir clinical profile

Atazanavir (ATV) qd versus efavirenz (EFV) qd with zidovudine plus lamivudine bid in treatment-naive patients Virologic response through week 48 (ITT)

Susceptibility profiles of I50L isolates

Drugs used to treat HIV infections (AIDS)

Currently approved NRTIs

NRTIs in development

Currently approved NNRTIs

NNRTIs in development

Currently approved PIs

PIs in development

VIREADTM (tenofovir disoproxil fumarate)

Study 903 % Patients < 400 Copies/mL

Study 903 % Patients < 400 Copies/mL

Study 903 % Patients < 50 Copies/mL

Study 903 Mean Change from Baseline in CD4

Study 903 Nucleoside Associated Toxicities

Study 903 Grade 3/4 Laboratory Abnormalitiesa

Study 903 Mean (95%CI) Change from Baseline in Triglycerides

Study 903 Mean (95% CI) Change from Baseline in Cholesterol

Study 903 Serum Creatinine

Study 903 Summary

Results from Clinical Trials: Percent With HIV RNA ?50 at 48 Weeks

Results from Clinical Trials: Percent With HIV RNA ?50 at 48 Weeks

Author: E. De Clercq

Email: tulkens@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/chaire-francqui/slides

Other information:
These slides are for information only and cannot be copied or used for any purpose without the authorization of Prof. E. De Clercq. Please, send your requests to <tulkens@facm.ucl.ac.be>

Download presentation as PDF file